

## Recombinant Human Mesothelin/MSLN (C-His) Catalog No: BP048

Description Recombinant Human Mesothelin is produced by Human 293 Cells. The target gene encoding E296-

D580 is expressed with a 10His tag at the C terminus.

**Expression System** Human cells

Alternative name Megakaryocyte potentiating factor; mesothelin; Pre-pro-megakaryocyte-potentiating factor; soluble

MPF mesothelin related protein; CAK1; MPF; MSLN; SMR; CAK1; CAK1 antigen

Accession No. Q13421 Predicted 37.6kDa

**Molecular Weight** 

Apparent Molecular Weight 35-45kDa, reducing conditions.

Quality Control Purity: greater than 95% as determined by reducing SDS-PAGE.

Endotoxin: less than 0.1 ng/μg (1 EU/μg) as determined by TAL test.

Formulation PBS, pH 7.4

Reconstitution It is not recommended to reconstitute to a concentration less than 100µg/ml.

Dissolve the lyophilized protein in distilled water.

Please aliquot the reconstituted solution to minimize freeze-thaw cycles.

**Shipping** The product is shipped at ambient temperature.

Upon receipt, store it immediately at the temperature listed below.

Storage Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks.

Reconstituted protein solution can be stored at 4-7°C for 2-7 days. Aliquots of reconstituted samples

are stable at < -20°C for 3 months.


Always centrifuge tubes before opening. Do not mix by vortex or pipetting.

Background Mesothelin (MSLN) is a cell surface glycoprotein that belongs to the mesothelin family. It can be

expressed by mesothelial cells of the serosa (pleura, pericardium, and peritoneum) and epithelial cells of the trachea, tonsils, fallopian tube, and kidneys. The Membrane-anchored form of mesothelin may play a role in cellular adhesion. Mesothelin is also found highly expressed in various cancers, including malignant mesothelioma, pancreatic or ovarian carcinoma, sarcomas and in some

gastrointestinal or pulmonary carcinomas. Due to its limited expression in normal tissues, mesothelin has been reported as an ideal tumor-associated marker for the development of targeted therapy.

**SDS-PAGE** 



M: Marker

1: Sample in reducing conditions

